New treatment attacks brain tumors from multiple angles

Traitors turn back into defenders

13-Nov-2024 - Glioblastoma is the most common kind of malignant brain tumor in adults. So far, no treatment has been able to make this aggressive tumor permanently disappear. The tumor cells are too varied, and the microenvironment is too tumor-friendly. Researchers at the University of Basel and University ...

Diabetes switch in DNA

Promising approach for personalised diabetes therapy

07-Nov-2024 - They are underestimated genetic control elements: it is known that changes in the genome can trigger diabetes. But now researchers at the University Hospital Ulm and the INSERM Cochin Institute in Paris have shown that a previously under-researched region of the genome also plays a crucial role ...

Water-shy proteins weaken protection against cancer

Special mutations in important protective proteins lead to the proteins being broken down longer and therefore faster

31-Oct-2024 - Cancer researchers at the Faculty of Medicine at the University of Freiburg have discovered that certain "non-stop mutations" make important protective proteins against cancer in the body longer, making them "water-shy". The proteins then become more unstable in the aqueous environment of the ...

A Mushroom for Colorectal Cancer Therapy

Plant fungus provides new drug with a new cellular target

22-Oct-2024 - Novel chemical compounds from a fungus could provide new perspectives for treating colorectal cancer, one of the most common and deadliest cancers worldwide. In the journal Angewandte Chemie, researchers have reported on the isolation and characterization of a previously unknown class of ...

Genespire raises €46.6 million in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic

One of the largest private Italian Biotech company financings to date

01-Oct-2024 - Genespire, a biotechnology company developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases, announced the closing of a €46.6 million (~$52 million) Series B financing, co-led by Sofinnova Partners, XGEN Venture and CDP Venture Capital through its Large Venture ...

Leveraging intercellular mitochondria transfer to boost cancer immunotherapies

A new cancer busting platform

17-Sep-2024 - An international team of researchers, led by Professor Luca Gattinoni at the Leibniz Institute for Immunotherapy (LIT), has developed an innovative mitochondrial transfer platform to supercharge CD8+ T cells, enabling them to overcome exhaustion and more effectively fight tumor cells. Cancer ...

When is the best time of day for cancer treatment?

Researchers are developing new methods to use the internal clock inside tumor cells to optimize cancer therapies

28-Aug-2024 - How effective medications are depends on various factors, including the time of day when they are administered. Why? Because our bodies don’t always function exactly the same. Instead, they follow the cycle set by their internal clock, otherwise known as circadian rhythm. But since each person’s ...

Skin flora as the key to cancer therapy?

22-Aug-2024 - Can the skin microbiome, also known as skin flora, influence the effectiveness of cancer therapy? Dr. Robin Reschke from the Department of Dermatology at Heidelberg University Hospital (UKHD) and the National Center for Tumor Diseases (NCT) in Heidelberg wants to find out. German Cancer Aid is ...

Exciting advance in stem cell therapy

New technique for manipulating stem cells opens door to novel treatments

20-Aug-2024 - A new technique developed by McGill researchers for mechanically manipulating stem cells could lead to new stem cell treatments, which have yet to fulfill their therapeutic potential. Stem cell therapy has been heralded as a new way to treat many diseases, ranging from multiple sclerosis, ...

Novel anti-cancer therapy: Prevention or reversal of cancer resistance

CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab

18-Jul-2024 - CatalYm announced the completion of a $150 million Series D financing. The oversubscribed round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s Growth Opportunities Fund (“Forbion Growth”), Omega Funds and Gilde Healthcare. Existing investors Jeito Capital, ...